New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 21, 2014
09:09 EDTAGENAgenus announces 'promising' Prophage G-200 Phase 2 results
Agenus announced that Phase 2 results of Prophage G-200 vaccine in recurrent patients with glioblastoma multiforme were hailed as "exciting" and a "very promising therapy" in an editorial published in Neuro-Oncology. The results of Agenusí Prophage vaccine Phase 2 study, published last month in Neuro-Oncology, demonstrated that more than 90% of the patients treated with the vaccine candidate were alive at six months. The median overall survival in these patients was approximately 11 months. The results of the Phase 2 trial have garnered the support of the National Cancer Institute. The study is actively enrolling and will offer the opportunity to provide important data to validate assessments of biomarkers and imaging criteria.
News For AGEN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 24, 2015
05:04 EDTAGENAgenus reports GSK Malaria vaccine receives positive opinion from CHMP of EMA
Subscribe for More Information
July 23, 2015
07:14 EDTAGENAgenus reports Q2 EPS (53c), consensus (15c)
Subscribe for More Information
July 20, 2015
07:02 EDTAGENAgenus acquires novel antibodies to immuno-oncology target CEACAM1
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use